Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

More Camden, N.J., Residents Using Needle Exchange Programs
A pilot needle exchange program in Camden, N.J., - one of four in the state - "was off to a slow start" when it began 18 months ago, but "now, 976 drug users have registered with the program - more people than those at the other pilot sites in Atlantic City, Newark or Paterson," the Cherry Hill Courier-Post reports. "In Camden, 854 people are living with HIV/AIDS, the eighth-highest number among New Jersey municipalities, according to the latest data from the state Department of Health and Senior Services. About a third of them were infected by dirty needles," the Courier-Post reports. Bob Baxter, who oversees Newark"s program, said needle exchanges provide "the most immediate benefit at the cheapest cost," in reducing the spread of blood-borne diseases. "While there"s no way to count the number of people who are no longer sharing needles because of the program, organizers say they hope to see their success correlate to lowered communicable disease rates," the article states (Hirsch, 7/20).
generic viagra online
Sen. Sessions To Give Floor Speeches On Judiciary As GOP Prepares For Sotomayor Debate
Sen. Jeff Sessions (R-Ala.), the ranking member on the Senate Judiciary Committee, on Wednesday is expected to outline the Republican Party"s vision for the judiciary and the kinds of judges the GOP supports for the Supreme Court in the first of a series of floor speeches, according to committee s, Roll Call reports. Although the speeches are not directly targeted at Supreme Court nominee Judge Sonia Sotomayor, Sessions said he hopes they will begin a "national dialogue" on the judiciary"s role ahead of her confirmation hearing, which is scheduled to begin July 13. Sessions is expected to give four to five speeches, which also will appear as opinion pieces in the Washington Times this week. His first speech will address his views on the foundation of a strong judiciary and judicial restraint. The later speeches will focus on President Obama"s call for judges who display "empathy" and other issues, according to Roll Call. The committee said the speeches "will address the fundamental issues that will be in play during the confirmation process" and "make the case for judicial restraint versus judicial activism."According to Roll Call, part of Sessions" motivation for giving the speeches is to clarify the definition of terms like "judicial restraint," "activist judge" and "empathy standard," phrases that frequently arise in debates over judges but might not be widely understood among judicial outsiders and the general public. Senators are expected to question Sotomayor on such topics during her confirmation hearing, and Sessions aims to define the context of the terms before the hearings begin, Roll Call reports. Senate Judiciary Committee Chair Patrick Leahy (D-Vt.) said that he is optimistic that Sotomayor"s hearings will remain bipartisan and that Republicans would not attempt to derail them by boycotting the hearings. He added that he believes GOP senators will participate in the hearings despite their complaints that they have not had enough time to prepare (Stanton, Roll Call, 6/17). Purchase zoloft to treat depression.
News of the day
Sleep Difficulties May Occur With Parental Presence At Bedtime
Parental presence at bedtimes appears to have a greater negative impact on infant sleep than actual co-sleeping, according to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
Oncology

DxNA Submits Its Rapid Detection Platform Test For H1N1 To FDA

DxNA announced that it has submitted a request to the FDA for Emergency Use Authorization (EUA) for its GeneSTAT(R) pathogen platform, for the detection of the H1N1 virus (known as swine flu). EUA allows for the early availability of important diagnostic and therapeutics tools to diagnose, treat, or prevent critical or life-threatening diseases or conditions, when an alternative or approved solution is not available(1). "Those touched by the flu are becoming increasingly aware that there is no accessible test for the H1N1 virus and that the currently available methods lack the capability to process large volumes of cases. We believe the availability of such a test would help assure concerned patients and families that they are taking the appropriate steps in combating this growing threat as cases continue to increase," said Phillip Grimm, Chief Executive Officer of DxNA. "This regulatory path provided by FDA allows early access to products with great potential like our GeneSTAT pathogen test platform, which we believe can provide a quick and efficient method to detect the H1N1 virus." Although the period of review can vary by product profile, existing applications, and nature of the emergency, the FDA acts upon EUA submissions in an expedited manner to potentially bring life-changing diagnostic and therapeutic tools to the public. DxNA has also developed a rapid, portable molecular test to detect H5 Avian Influenza for markets around the world. That test is now being validated by the Chinese government and other global health organizations. The GeneSTAT(R) platform includes a portable device that offers remote usage to rapidly detect pathogens where outbreaks are suspected. The user-friendly device can be used in gateway airports, at local health departments and schools, where on-site rapid and non-invasive screening for highly contagious pathogens is advised. The GeneSTAT(R) test module requires a simple swab of the mouth, nose or throat. The Company is developing a number of follow-on tests to detect pathogens that may affect people and agriculture. Through its rapid, precise, on-site polymerase chain reaction (PCR) genetic testing capabilities, GeneSTAT technology facilitates the rapid detection of pathogens and viruses. The World Health Organization has highlighted rapid detection of pandemics such as swine flu as "crucial" for the rapid implementation of measures "to stop the pandemic at its and to prevent millions of deaths, social disruption, and economic loss(2) About GeneSTAT(R) DxNA"s GeneSTAT diagnostic platform technology allows individuals with approximately five minutes of training to conduct accurate real-time diagnostic testing almost anywhere. With the GeneSTAT platform, PCR -- previously performed in large clinical laboratories by highly-skilled personnel -- can be performed by almost anyone, in virtually any location, including airports, laboratories, clinics, or physician"s offices. Furthermore, testing is not limited to developed regions like the United States, Europe and Japan but also in less-developed rural and economically challenged regions. Designed with economy in mind, GeneSTAT is inherently less costly than the PCR devices typical of large clinical laboratories. About DxNA DxNA, based in St. George, Utah, and with offices in New York City is a groundbreaking molecular diagnostics company that develops and distributes portable, fully-integrated systems and tests for genetic analysis in the medical, agricultural, and biosecurity markets. The Company"s systems and technologies enable rapid and precise genetic testing to take place on-site by allowing for otherwise complex, manual, laboratory procedures to be performed anywhere. DxNA, together with its distinguished advisory board consisting of Nirbhay Kumar, Ph.D., Paul Blumenthal, M.D., M.P.H., Anthony R. Torres, M.D., and Richard Webby, Ph.D., is working to commercialize its GeneSTAT diagnostic technology for rapid PCR detection applications throughout the world DxNA, together with its distinguished advisory board consisting of Nirbhay Kumar, Ph.D., Paul Blumenthal, M.D., M.P.H., Anthony R. Torres, M.D., and Richard Webby, Ph.D., is working to commercialize its GeneSTAT diagnostic technology for rapid PCR detection applications throughout the world. References (1) Emergency Use Authorization of Medical Products" Food and Drug Administration, July 2007 (2) "Global Surveillance During an Influenza Pandemic, Version 1" World Health Organization Global Influenza Programme, April 2009 DxNA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009